Abstract CT188: A Phase I Trial of AVA6000, a Fibroblast Activation Protein (Fap)-Released and Tumor Microenvironment (Tme)-Targeted Doxorubicin Peptide Drug Conjugate in Patients with FAP-positive Solid Tumors
CANCER RESEARCH（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined